Skip to content
Review Open access

Transient Elastography for Liver Fibrosis and Steatosis in Inflammatory Bowel Disease: Current Evidence, Clinical Implications, and Future Directions

Sep 2026 · Journal of Enterocolitis · 0 citations

Abstract

Inflammatory bowel disease (IBD) is frequently complicated by hepatobiliary conditions, including metabolic dysfunction-associated steatotic liver disease (MASLD), drug-induced liver injury, primary sclerosing cholangitis, and autoimmune liver disease. However, systematic liver assessment remains underused, and serum indices such as FIB-4 may be confounded by IBD-related thrombocytosis. Transient elastography (TE) quantifies liver stiffness measurement (LSM) for fibrosis and the controlled attenuation parameter (CAP) for steatosis through a rapid, noninvasive outpatient examination. This narrative review synthesizes evidence on the prevalence of fibrosis and steatosis, associated risk factors, the effects of IBD therapies, and the clinical utility of TE-based screening, drawing on original studies that used FibroScan®-based LSM and/or CAP in adult patients with IBD; studies using other elastography modalities were excluded. Across 13 studies involving more than 2,700 patients with IBD, the prevalence of significant fibrosis (F≥2) clustered around 4–12% (range, ~1–24%, depending on the threshold), while steatosis was detected in 29–46%. Anti-TNF therapy was associated with a lower prevalence of fibrosis, whereas cumulative corticosteroid exposure increased the risk of both fibrosis and steatosis. Two matched-control studies confirmed that IBD independently confers an increased hepatic risk: one reported steatosis in 42.0% versus 32.7% and advanced fibrosis in 9.5% versus 2.3% of controls (adjusted odds ratio [aOR] for steatosis, 1.99), while ELASTIBD reported significant fibrosis in 12.3% versus 4.2% (aOR, 3.31) and steatosis in 41.4% versus 28.3% (aOR, 2.51) compared with matched controls. TE therefore provides actionable information beyond standard liver function tests and should be integrated into IBD follow-up, particularly for patients with prolonged corticosteroid exposure, metabolic comorbidities, or longstanding disease, while standardization of cutoff values and longitudinal data remain research priorities.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.